prazosin has been researched along with Depression in 24 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The findings indicate that alcohol withdrawal symptoms are a significant moderator of prazosin treatment response for alcohol use outcomes and for associated symptoms of alcohol craving, anxiety, and mood symptoms." | 5.41 | Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms. ( Angarita, GA; Fogelman, N; Fox, HC; Hermes, G; Milivojevic, V; Morgan, PM; Sinha, R; Wemm, S, 2021) |
| "This study investigates the effect of the petroleum ether, chloroform, and ethyl acetate fractions of the total ethanolic extract of Convolvulus pluricaulis Choisy (Family: Convolvulaceae) on depression in mice." | 3.74 | Evaluation of the antidepressant-like activity of Convolvulus pluricaulis choisy in the mouse forced swim and tail suspension tests. ( Dhingra, D; Valecha, R, 2007) |
| "Clinical studies have shown that folic acid plays a role in the pathophysiology of depression." | 3.74 | Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. ( Brocardo, PS; Budni, J; Kaster, MP; Rodrigues, AL; Santos, AR, 2008) |
| "Prazosin and placebo were administered on two different occasions in the early afternoon followed two hours later by the E-Stroop." | 2.72 | Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. ( Allison, N; Kanter, ED; Lowe, K; Martin, P; McFall, MM; Peskind, ER; Raskind, MA; Taylor, FB; Thompson, C; Williams, J, 2006) |
| "For those with PTSD, a suggested treatment approach is long-term supportive psychotherapy with drug treatment directed at reducing the most disruptive symptoms, such as insomnia, nightmares, and irritability or psychosis." | 1.43 | Medical Approach to the Management of Traumatized Refugees. ( Kinzie, JD, 2016) |
| "Carvacrol (cvc) was administered orally at single doses of 12." | 1.37 | Antidepressant-like effect of carvacrol (5-Isopropyl-2-methylphenol) in mice: involvement of dopaminergic system. ( de Sousa, DP; de Sousa, FC; de Vasconcelos, SM; Fonteles, MM; Macedo, DS; Melo, FH; Moura, BA; Viana, GS, 2011) |
| "Citalopram was inactive when given alone but it potentiated the antidepressant-like effect of MK-801." | 1.28 | Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. ( Maj, J; Rogóz, Z; Skuza, G; Sowińska, H, 1992) |
| "Bupropion is a novel antidepressant, distinct from tricyclic antidepressants both neurochemically and behaviorally." | 1.28 | Antidepressant profile of bupropion and three metabolites in mice. ( Colin, JN; Lacomblez, L; Martin, P; Massol, J; Puech, AJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Sinha, R | 1 |
| Wemm, S | 1 |
| Fogelman, N | 1 |
| Milivojevic, V | 1 |
| Morgan, PM | 1 |
| Angarita, GA | 1 |
| Hermes, G | 1 |
| Fox, HC | 1 |
| Lin, M | 1 |
| Li, H | 1 |
| Zhao, Y | 1 |
| Cai, E | 1 |
| Zhu, H | 1 |
| Gao, Y | 1 |
| Liu, S | 1 |
| Yang, H | 1 |
| Zhang, L | 1 |
| Tang, G | 1 |
| Wang, R | 1 |
| Siddiqui, PJA | 1 |
| Khan, A | 1 |
| Uddin, N | 1 |
| Khaliq, S | 1 |
| Rasheed, M | 1 |
| Nawaz, S | 1 |
| Hanif, M | 1 |
| Dar, A | 1 |
| DeWeerdt, S | 1 |
| Saleem, AM | 1 |
| Taufik Hidayat, M | 1 |
| Jais, AM | 1 |
| Fakurazi, S | 1 |
| Moklas, MA | 1 |
| Sulaiman, MR | 1 |
| Amom, Z | 1 |
| Basir, R | 1 |
| Sekio, M | 1 |
| Seki, K | 1 |
| Kinzie, JD | 1 |
| Zhang, HT | 1 |
| Whisler, LR | 1 |
| Huang, Y | 1 |
| Xiang, Y | 1 |
| O'Donnell, JM | 1 |
| Machado, DG | 2 |
| Bettio, LE | 1 |
| Cunha, MP | 1 |
| Capra, JC | 1 |
| Dalmarco, JB | 1 |
| Pizzolatti, MG | 2 |
| Rodrigues, AL | 3 |
| Freitas, AE | 1 |
| Budni, J | 2 |
| Lobato, KR | 1 |
| Binfaré, RW | 1 |
| Jacinto, J | 1 |
| Veronezi, PO | 1 |
| Melo, FH | 1 |
| Moura, BA | 1 |
| de Sousa, DP | 1 |
| de Vasconcelos, SM | 1 |
| Macedo, DS | 1 |
| Fonteles, MM | 1 |
| Viana, GS | 1 |
| de Sousa, FC | 1 |
| Yi, LT | 1 |
| Xu, HL | 1 |
| Feng, J | 1 |
| Zhan, X | 1 |
| Zhou, LP | 1 |
| Cui, CC | 1 |
| Souza, LC | 1 |
| de Gomes, MG | 1 |
| Goes, AT | 1 |
| Del Fabbro, L | 1 |
| Filho, CB | 1 |
| Boeira, SP | 1 |
| Jesse, CR | 1 |
| Taylor, FB | 1 |
| Lowe, K | 1 |
| Thompson, C | 1 |
| McFall, MM | 1 |
| Peskind, ER | 1 |
| Kanter, ED | 1 |
| Allison, N | 1 |
| Williams, J | 1 |
| Martin, P | 3 |
| Raskind, MA | 1 |
| Dhingra, D | 1 |
| Valecha, R | 1 |
| Brocardo, PS | 1 |
| Kaster, MP | 1 |
| Santos, AR | 1 |
| Wang, Y | 1 |
| Jeng, CH | 1 |
| Lin, JC | 1 |
| Wang, JY | 1 |
| Song, DK | 1 |
| Suh, HW | 1 |
| Jung, JS | 1 |
| Wie, MB | 1 |
| Son, KH | 1 |
| Kim, YH | 1 |
| Stone, EA | 1 |
| Quartermain, D | 1 |
| Bolzano, K | 1 |
| Maj, J | 1 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Sowińska, H | 1 |
| Hascoët, M | 1 |
| Bourin, M | 1 |
| Bradwejn, J | 1 |
| Massol, J | 1 |
| Colin, JN | 1 |
| Lacomblez, L | 1 |
| Puech, AJ | 1 |
| Poncelet, M | 1 |
| Danti, S | 1 |
| Simon, P | 1 |
| Soubrié, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms[NCT04793685] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for prazosin and Depression
| Article | Year |
|---|---|
Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcohol Abstinence; Alcoholism; Anxiety; Central Ner | 2021 |
Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Circadian Rhythm; Cues; Depre | 2006 |
22 other studies available for prazosin and Depression
| Article | Year |
|---|---|
Ergosteryl 2-naphthoate, An Ergosterol Derivative, Exhibits Antidepressant Effects Mediated by the Modification of GABAergic and Glutamatergic Systems.
Topics: Animals; Antidepressive Agents; Bicuculline; Central Nervous System; Depression; Dopamine; Dose-Resp | 2017 |
Antidepressant-like deliverables from the sea: evidence on the efficacy of three different brown seaweeds via involvement of monoaminergic system.
Topics: Adrenergic Antagonists; Animals; Antidepressive Agents; Benzazepines; Depression; Dopamine Antagonis | 2017 |
Mood disorders: the dark night.
Topics: Affect; Amygdala; Bipolar Disorder; Circadian Rhythm; Depression; Dreams; Electroencephalography; Gy | 2013 |
Involvement of monoaminergic system in the antidepressant-like effect of aqueous extract of Channa striatus in mice.
Topics: Adrenergic Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonist | 2013 |
Lipopolysaccharide-induced depressive-like behavior is associated with α₁-adrenoceptor dependent downregulation of the membrane GluR1 subunit in the mouse medial prefrontal cortex and ventral tegmental area.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Cell Membrane; Depression; Disease Models, Animal; | 2014 |
Medical Approach to the Management of Traumatized Refugees.
Topics: Adult; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Clonidine; Depression; Dreams; Dru | 2016 |
Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-An | 2009 |
Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2009 |
Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: evidence for the involvement of the monoaminergic system.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antidepressive Agents; Biogenic Monoami | 2010 |
Antidepressant-like effect of carvacrol (5-Isopropyl-2-methylphenol) in mice: involvement of dopaminergic system.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepre | 2011 |
Involvement of monoaminergic systems in the antidepressant-like effect of nobiletin.
Topics: Adrenergic Antagonists; Animals; Antidepressive Agents; Benzazepines; Cyproheptadine; Depression; Di | 2011 |
Evidence for the involvement of the serotonergic 5-HT(1A) receptors in the antidepressant-like effect caused by hesperidin in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Exploratory Behavior; Fluoxetine; Hesp | 2013 |
Evaluation of the antidepressant-like activity of Convolvulus pluricaulis choisy in the mouse forced swim and tail suspension tests.
Topics: Acetates; Alkanes; Animals; Antidepressive Agents; Chloroform; Convolvulus; Depression; Fenclonine; | 2007 |
Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Depression; Female; Fenclonine; Fluoxe | 2008 |
Methamphetamine facilitates ethanol-induced depressions in cerebellar Purkinje neurons of prazocin- or DSP4-treated rats.
Topics: Action Potentials; Animals; Benzylamines; Cerebellum; Depression; Ethanol; Male; Methamphetamine; Pr | 1995 |
Antidepressant-like effects of p-synephrine in mouse models of immobility tests.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antidepressive Agent | 1996 |
Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Behavi | 1999 |
[A clinical study with prazosin].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Benzothiadiazines; Depression; Diuretics; Drug Therapy, C | 1978 |
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Haloperidol; Imipramine | 1992 |
Behavioral models in mice. Implication of the alpha noradrenergic system.
Topics: Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Clonidine; Depression; Dioxanes; Hydroxamic | 1991 |
Antidepressant profile of bupropion and three metabolites in mice.
Topics: Animals; Antidepressive Agents; Apomorphine; Body Temperature; Bupropion; Depression; Male; Mice; Mo | 1990 |
Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals.
Topics: Animals; Antidepressive Agents; Brain; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; | 1987 |